Yeh JJ - Search Results

1

Gastrointestinal Malignancy: Genetic Implications to Clinical Applications.

Trembath HE, Yeh JJ, Lopez NE. Trembath HE, et al. Among authors: yeh jj. Cancer Treat Res. 2024;192:305-418. doi: 10.1007/978-3-031-61238-1_15. Cancer Treat Res. 2024. PMID: 39212927 Review.

2

Activation and involvement of Ral GTPases in colorectal cancer.

Martin TD, Samuel JC, Routh ED, Der CJ, Yeh JJ. Martin TD, et al. Among authors: yeh jj. Cancer Res. 2011 Jan 1;71(1):206-15. doi: 10.1158/0008-5472.CAN-10-1517. Cancer Res. 2011. PMID: 21199803 Free PMC article.

3

Gastrointestinal Malignancy: Genetic Implications to Clinical Applications.

Lopez NE, Yeh JJ. Lopez NE, et al. Among authors: yeh jj. Cancer Treat Res. 2016;168:393-479. doi: 10.1007/978-3-319-34244-3_19. Cancer Treat Res. 2016. PMID: 29206386 Review.

4

Altered exocrine function can drive adipose wasting in early pancreatic cancer.

Danai LV, Babic A, Rosenthal MH, Dennstedt EA, Muir A, Lien EC, Mayers JR, Tai K, Lau AN, Jones-Sali P, Prado CM, Petersen GM, Takahashi N, Sugimoto M, Yeh JJ, Lopez N, Bardeesy N, Fernandez-Del Castillo C, Liss AS, Koong AC, Bui J, Yuan C, Welch MW, Brais LK, Kulke MH, Dennis C, Clish CB, Wolpin BM, Vander Heiden MG. Danai LV, et al. Among authors: yeh jj. Nature. 2018 Jun;558(7711):600-604. doi: 10.1038/s41586-018-0235-7. Epub 2018 Jun 20. Nature. 2018. PMID: 29925948 Free PMC article.

5

Myofibroblastic cancer-associated fibroblast subtype heterogeneity in pancreatic cancer.

Kearney JF, Trembath HE, Chan PS, Morrison AB, Xu Y, Luan CF, McCabe IC, Zarmer SA, Kim HJ, Peng XL, Yeh JJ. Kearney JF, et al. Among authors: yeh jj. J Surg Oncol. 2024 Apr;129(5):860-868. doi: 10.1002/jso.27582. Epub 2024 Jan 17. J Surg Oncol. 2024. PMID: 38233984

6

Updates in Molecular Profiling of Pancreatic Ductal Adenocarcinoma.

Lee JJ, Yeh JJ. Lee JJ, et al. Among authors: yeh jj. Surg Clin North Am. 2024 Oct;104(5):939-950. doi: 10.1016/j.suc.2024.04.001. Epub 2024 May 16. Surg Clin North Am. 2024. PMID: 39237169 Review.

7

KRAS/BRAF mutation status and ERK1/2 activation as biomarkers for MEK1/2 inhibitor therapy in colorectal cancer.

Yeh JJ, Routh ED, Rubinas T, Peacock J, Martin TD, Shen XJ, Sandler RS, Kim HJ, Keku TO, Der CJ. Yeh JJ, et al. Mol Cancer Ther. 2009 Apr;8(4):834-43. doi: 10.1158/1535-7163.MCT-08-0972. Mol Cancer Ther. 2009. PMID: 19372556 Free PMC article.

8

Prognostic signature for pancreatic cancer: are we close?

Yeh JJ. Yeh JJ. Future Oncol. 2009 Apr;5(3):313-21. doi: 10.2217/fon.09.12. Future Oncol. 2009. PMID: 19374539 Review.

9

A comparative evaluation of ultrasound molecular imaging, perfusion imaging, and volume measurements in evaluating response to therapy in patient-derived xenografts.

Streeter JE, Herrera-Loeza SG, Neel NF, Yeh JJ, Dayton PA. Streeter JE, et al. Among authors: yeh jj. Technol Cancer Res Treat. 2013 Aug;12(4):311-21. doi: 10.7785/tcrt.2012.500321. Epub 2013 Jan 25. Technol Cancer Res Treat. 2013. PMID: 23369156 Free PMC article.

10

GSK-3α promotes oncogenic KRAS function in pancreatic cancer via TAK1-TAB stabilization and regulation of noncanonical NF-κB.

Bang D, Wilson W, Ryan M, Yeh JJ, Baldwin AS. Bang D, et al. Among authors: yeh jj. Cancer Discov. 2013 Jun;3(6):690-703. doi: 10.1158/2159-8290.CD-12-0541. Epub 2013 Apr 1. Cancer Discov. 2013. PMID: 23547054 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

242 results

Search Page

Filters